论文部分内容阅读
目的:剖析干扰素α2b雾化吸入疗法在小儿上呼吸道病毒性感染中的应用价值。方法:以2015年10月至2017年4月本科接诊的110例上呼吸道病毒性感染患儿为研究对象,采用抽签的形式对其进行分组:研究组、对照组各55例。予以所有病患常规抗病毒治疗,研究组同时加用干扰素α2b雾化吸入疗法。观察两组咳嗽咳痰等症状的缓解情况,比较临床疗效。结果:研究组的退热时间与咳嗽咳痰消失时间均明显比对照组短,组间差异显著(P<0.05)。研究组疗效的总有效率为98.18%,明显比对照组的89.09%高,组间差异显著(P<0.05)。结论:于小儿上呼吸道病毒性感染中积极应用干扰素α2b雾化吸入疗法,有助于改善患儿的临床症状,提高治疗效果。
Objective: To investigate the value of interferon α2b inhalation therapy in children with upper respiratory tract viral infection. Methods: From October 2015 to April 2017, 110 children with upper respiratory tract viral infection admitted to undergraduate education were enrolled in this study. The patients were divided into two groups by random sampling: the study group and the control group, each with 55 cases. To all patients with conventional antiviral therapy, the study group also added interferon α 2b atomization inhalation therapy. To observe the relief of symptoms such as cough and sputum in two groups and compare the clinical curative effect. Results: The antipyretic time of the study group was significantly shorter than that of the control group (P <0.05). The total effective rate of the study group was 98.18%, significantly higher than 89.09% of the control group, significant difference between groups (P <0.05). Conclusion: The positive use of IFN-α2b aerosol inhalation therapy in children with upper respiratory tract viral infections can help to improve the clinical symptoms of children and improve the therapeutic effect.